NYSE:NVTAInVitae Stock Price, Forecast & News

$16.54

-0.97 (-5.54 %)

(As of 05/26/2020 04:00 PM ET)

Add

Compare

Today's Range

$16.50

Now: $16.54▼

$18.19

50-Day Range

$12.62

MA: $15.60▼

$17.85

52-Week Range

$7.41

Now: $16.54▼

$28.75

Volume2.52 million shs

Average Volume3.14 million shs

Market Capitalization$2.07 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.09

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
InVitae has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.40, InVitae has a potential upside of 59.6% from its current price of $16.54.
Amount of Analyst Coverage
InVitae has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
InVitae has received 414 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
InVitae has received 414 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
InVitae has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote “Outperform” if you believe NVTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
InVitae does not currently pay a dividend.
Dividend Growth
InVitae does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InVitae insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,552,203.00 in company stock.
Percentage Held by Insiders
Only 5.70% of the stock of InVitae is held by insiders.
Percentage Held by Institutions
81.68% of the stock of InVitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for InVitae are expected to grow in the coming year, from ($2.51) to ($1.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of InVitae is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InVitae is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InVitae has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.51 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:NVTA

Previous Symbol

CUSIPN/A

CIK1501134

Webwww.invitae.com

Phone415-374-7782

Debt

Debt-to-Equity Ratio0.97

Current Ratio2.95

Quick Ratio2.95

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$216.82 million

Price / Sales9.54

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.93 per share

Price / Book4.21

Profitability

EPS (Most Recent Fiscal Year)($2.28)

Net Income$-241,960,000.00

Net Margins-127.42%

Return on Equity-69.95%

Return on Assets-35.42%

Miscellaneous

Employees1,300

Outstanding Shares125,013,000

Market Cap$2.07 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

InVitae (NYSE:NVTA) Frequently Asked Questions

How has InVitae's stock been impacted by COVID-19 (Coronavirus)?

InVitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 4.4% and is now trading at $16.54. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of InVitae?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InVitae.

When is InVitae's next earnings date?

InVitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for InVitae.

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) issued its quarterly earnings data on Tuesday, May, 5th. The medical research company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.04. The medical research company had revenue of $64.25 million for the quarter, compared to analyst estimates of $59.41 million. InVitae had a negative net margin of 127.42% and a negative return on equity of 69.95%. The business's revenue was up 58.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.47) earnings per share. View InVitae's earnings history.

What price target have analysts set for NVTA?

5 brokers have issued 12 month target prices for InVitae's shares. Their forecasts range from $20.00 to $32.00. On average, they anticipate InVitae's stock price to reach $26.40 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View analysts' price targets for InVitae.

What are Wall Street analysts saying about InVitae stock?

Here are some recent quotes from research analysts about InVitae stock:

1. According to Zacks Investment Research, "Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California. " (4/7/2020)
2. Chardan Capital analysts commented, "We liked the new strategic partnerships with biopharma companies, growth in billable tests, and improvement in average cost per sample during the quarter. We see NVTA as a leader among high-growth digital health companies and we see the stock as mispriced compared with its valuation peers. We see the potential for over 50% upside in the name in the next 12 months as Management executes and the stock trades more in line with its valuation comparable." (6/11/2019)

Has InVitae been receiving favorable news coverage?

Press coverage about NVTA stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. InVitae earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutInVitae.

Who are some of InVitae's key competitors?

Some companies that are related to InVitae include ELEKTA AB/ADR (EKTAY), Natera (NTRA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC) and Miragen Therapeutics (MGEN). View all competitors.

What other stocks do shareholders of InVitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

Who are InVitae's key executives?

InVitae's management team includes the following people:

Dr. Randal W. Scott, Exec. Chairman (Age 61)
Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
Mr. Lee Bendekgey, Sec. & COO (Age 61)
Ms. Laura D'Angelo, Head of Investor Relations

When did InVitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are InVitae's major shareholders?

InVitae's stock is owned by a number of institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.47%), Sumitomo Mitsui Trust Holdings Inc. (12.80%), BlackRock Inc. (6.03%), State Street Corp (4.91%), Casdin Capital LLC (2.78%) and Clearbridge Investments LLC (1.70%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View institutional ownership trends for InVitae.

Which institutional investors are selling InVitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., Morgan Stanley, Rafferty Asset Management LLC, Casdin Capital LLC, and Deutsche Bank AG. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida. View insider buying and selling activity for InVitae.

Which institutional investors are buying InVitae stock?

NVTA stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Bank of New York Mellon Corp, Nuveen Asset Management LLC, UBS Group AG, Clearbridge Investments LLC, Geode Capital Management LLC, and Oppenheimer & Co. Inc.. View insider buying and selling activity for InVitae.

How do I buy shares of InVitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InVitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $16.54.

How big of a company is InVitae?

InVitae has a market capitalization of $2.07 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

What is InVitae's official website?

The official website for InVitae is www.invitae.com.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff